MedTrace Logo

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

NCT05037045 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2024-11-12

No results posted yet for this study

Summary

1. This is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM.
2. T2DM patients and healthy subjects were recruited to identify genotypes and detect the level of T2DM susceptibility genes expression levels in the plasma of healthy participants and T2DM patients.
3. This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.

Conditions

Interventions

DRUG

GLP-1 receptor agonist

GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM

Sponsors & Collaborators

  • The Affiliated Hospital of Xuzhou Medical University

    lead OTHER

Principal Investigators

  • Renhao Wang, Ph.D · The Affiliated Hospital of Xuzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2023-10-01
Completion
2024-01-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05037045 on ClinicalTrials.gov